Literature DB >> 24139698

Neuroradiologic correlates of clinical disability and progression in the X-linked leukodystrophy Pelizaeus-Merzbacher disease.

Jeremy J Laukka1, Jeffrey A Stanley, James Y Garbern, Angela Trepanier, Grace Hobson, Tori Lafleur, Alexander Gow, John Kamholz.   

Abstract

OBJECTIVE: To determine whether quantitative measure of magnetic resonance imaging data from patients with the inherited leukodystrophy, Pelizaeus-Merzbacher disease (PMD) correlates with clinical severity or progression.
METHODS: In our current work we have analyzed the clinical phenotypes and MRI scans of 51 male patients with PMD and 10 female carriers for whom the PLP1 genotype had been determined. In addition, we developed a 32-point functional disability scoring (FDS) system for PMD, and validated it for inter-rater reliability. Using conventional T1- and T2-weighted MRI images of the whole brain, we measured white matter and total brain volume (WMV and TBV), inter-caudate ratio (ICR), and corpus callosum area.
RESULTS: There was a significant positive correlation of FDS with white matter fraction (WMV/TBV) and corpus callosum area. Also, when applying a median split based on FDS, patients with lower FDS showed reduced white matter fraction and corpus callosum area, and increased ICR compared to patients with relatively higher FDS, regardless of age.
CONCLUSION: Although this patient population is heterogeneous, with multiple genetic and molecular mechanisms causing PMD, these data imply that white matter atrophy is a major pathological determinant of the clinical disability in most patients. Development of reliable non-invasive quantitative biomarkers of disease activity would be useful not only for following the natural history of the disease, but also raising the potential for evaluating future therapies.
© 2013.

Entities:  

Keywords:  Clinical disability; Genetics; Magnetic resonance imaging; Pelizaeus–Merzbacher disease; Proteolipid protein; White matter atrophy

Mesh:

Substances:

Year:  2013        PMID: 24139698      PMCID: PMC3969727          DOI: 10.1016/j.jns.2013.08.030

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  36 in total

1.  PELIZAEUS-MERZBACHER DISEASE. A STUDY IN NOSOLOGY.

Authors:  W ZEMAN; W DEMYER; H F FALLS
Journal:  J Neuropathol Exp Neurol       Date:  1964-04       Impact factor: 3.685

Review 2.  Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis.

Authors:  J Y Garbern
Journal:  Cell Mol Life Sci       Date:  2007-01       Impact factor: 9.261

Review 3.  The PLP mutants from mouse to man.

Authors:  Ian D Duncan
Journal:  J Neurol Sci       Date:  2004-11-24       Impact factor: 3.181

4.  Astrocytic hypertrophy in dysmyelination influences the diffusion anisotropy of white matter.

Authors:  Laura A Harsan; Patrick Poulet; Blandine Guignard; Nathalie Parizel; Robert P Skoff; M Said Ghandour
Journal:  J Neurosci Res       Date:  2007-04       Impact factor: 4.164

5.  An MRI and MRS study of Pelizaeus-Merzbacher disease.

Authors:  A Nezu; S Kimura; S Takeshita; H Osaka; K Kimura; K Inoue
Journal:  Pediatr Neurol       Date:  1998-04       Impact factor: 3.372

6.  Axonal swellings and degeneration in mice lacking the major proteolipid of myelin.

Authors:  I Griffiths; M Klugmann; T Anderson; D Yool; C Thomson; M H Schwab; A Schneider; F Zimmermann; M McCulloch; N Nadon; K A Nave
Journal:  Science       Date:  1998-06-05       Impact factor: 47.728

7.  Validation of linear cerebral atrophy markers in multiple sclerosis.

Authors:  H Butzkueven; S C Kolbe; D J Jolley; J Y Brown; M J Cook; I A F van der Mei; P S Groom; J Carey; J Eckholdt; J P Rubio; B V Taylor; P J Mitchell; G F Egan; T J Kilpatrick
Journal:  J Clin Neurosci       Date:  2008-02       Impact factor: 1.961

Review 8.  The molecular and cellular defects underlying Pelizaeus-Merzbacher disease.

Authors:  Karen J Woodward
Journal:  Expert Rev Mol Med       Date:  2008-05-19       Impact factor: 5.600

9.  Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease.

Authors:  Adam M Brickman; Lawrence S Honig; Nikolaos Scarmeas; Oksana Tatarina; Linda Sanders; Marilyn S Albert; Jason Brandt; Deborah Blacker; Yaakov Stern
Journal:  Arch Neurol       Date:  2008-09

Review 10.  Current concepts of PLP and its role in the nervous system.

Authors:  I Griffiths; M Klugmann; T Anderson; C Thomson; D Vouyiouklis; K A Nave
Journal:  Microsc Res Tech       Date:  1998-06-01       Impact factor: 2.769

View more
  12 in total

1.  Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes.

Authors:  Zachary S Nevin; Daniel C Factor; Robert T Karl; Panagiotis Douvaras; Jeremy Laukka; Martha S Windrem; Steven A Goldman; Valentina Fossati; Grace M Hobson; Paul J Tesar
Journal:  Am J Hum Genet       Date:  2017-03-30       Impact factor: 11.025

2.  Auditory function in Pelizaeus-Merzbacher disease.

Authors:  Thierry Morlet; Kyoko Nagao; S Charles Bean; Sara E Mora; Sarah E Hopkins; Grace M Hobson
Journal:  J Neurol       Date:  2018-05-03       Impact factor: 4.849

3.  PMD patient mutations reveal a long-distance intronic interaction that regulates PLP1/DM20 alternative splicing.

Authors:  Jennifer R Taube; Karen Sperle; Linda Banser; Pavel Seeman; Barbra Charina V Cavan; James Y Garbern; Grace M Hobson
Journal:  Hum Mol Genet       Date:  2014-06-01       Impact factor: 6.150

Review 4.  Neurogenetics of Pelizaeus-Merzbacher disease.

Authors:  M Joana Osório; Steven A Goldman
Journal:  Handb Clin Neurol       Date:  2018

Review 5.  Hypomyelinating leukodystrophies - unravelling myelin biology.

Authors:  Nicole I Wolf; Charles Ffrench-Constant; Marjo S van der Knaap
Journal:  Nat Rev Neurol       Date:  2020-12-15       Impact factor: 42.937

6.  Pathology of the neurovascular unit in leukodystrophies.

Authors:  Parand Zarekiani; Marjolein Breur; Nicole I Wolf; Helga E de Vries; Marjo S van der Knaap; Marianna Bugiani
Journal:  Acta Neuropathol Commun       Date:  2021-06-03       Impact factor: 7.801

7.  Altered PLP1 splicing causes hypomyelination of early myelinating structures.

Authors:  Sietske H Kevelam; Jennifer R Taube; Rosalina M L van Spaendonk; Enrico Bertini; Karen Sperle; Mark Tarnopolsky; Davide Tonduti; Enza Maria Valente; Lorena Travaglini; Erik A Sistermans; Geneviève Bernard; Coriene E Catsman-Berrevoets; Clara D M van Karnebeek; John R Østergaard; Richard L Friederich; Mahmoud Fawzi Elsaid; Jolanda H Schieving; Maja Tarailo-Graovac; Simona Orcesi; Marjan E Steenweg; Carola G M van Berkel; Quinten Waisfisz; Truus E M Abbink; Marjo S van der Knaap; Grace M Hobson; Nicole I Wolf
Journal:  Ann Clin Transl Neurol       Date:  2015-05-01       Impact factor: 4.511

8.  Morpholino Antisense Oligomers as a Potential Therapeutic Option for the Correction of Alternative Splicing in PMD, SPG2, and HEMS.

Authors:  Stephanie Tantzer; Karen Sperle; Kaitlin Kenaley; Jennifer Taube; Grace M Hobson
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-05       Impact factor: 8.886

9.  Expanding the Clinical and Mutational Spectrum of the PLP1-Related Hypomyelination of Early Myelinated Structures (HEMS).

Authors:  Francesco Nicita; Chiara Aiello; Gessica Vasco; Massimiliano Valeriani; Fabrizia Stregapede; Andrea Sancesario; Michela Armando; Enrico Bertini
Journal:  Brain Sci       Date:  2021-01-13

10.  Clinical and mutational spectrum of Colombian patients with Pelizaeus Merzbacher Disease.

Authors:  Harvy Mauricio Velasco Parra; Silvia Juliana Maradei Anaya; Johanna Carolina Acosta Guio; Clara Eugenia Arteaga Diaz; Juan Carlos Prieto Rivera
Journal:  Colomb Med (Cali)       Date:  2018-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.